Keyphrases
Phase II Trial
99%
Eastern Cooperative Oncology Group
64%
Cisplatin
63%
Paclitaxel
62%
Chemotherapy
61%
Germ Cell Tumor
55%
Vinblastine
46%
Ifosfamide
45%
Phase II Study
44%
Hormone-sensitive Prostate Cancer
42%
Urothelium
41%
Combination Chemotherapy
35%
Prostate Cancer
28%
Gemcitabine
28%
Advanced Carcinoma
25%
Overall Survival
25%
Retroperitoneal Lymph Node Dissection (RPLND)
25%
Doxorubicin
25%
Etoposide
23%
Advanced Urothelial Cancer
23%
Testicular Cancer
22%
Advanced Urothelial Carcinoma
21%
Everolimus
20%
Methotrexate
20%
Bladder Cancer
20%
Confidence Interval
20%
Response Rate
20%
Objective Response
20%
Docetaxel
20%
Median Survival
19%
Prostate-specific Antigen
19%
Salvage Therapy
19%
Combination Regimen
18%
Partial Response
17%
Gallium Nitride
17%
Advanced Bladder Cancer
17%
Advanced Renal Cell Carcinoma
16%
Group Studies
16%
Transitional Cell Carcinoma of the Urothelium
16%
Dose-limiting Toxicity
16%
Carboplatin
16%
High-dose Chemotherapy
15%
Oncology
15%
Metastatic Urothelial Carcinoma
15%
Clinical Stage I
15%
Pharmacokinetic Study
15%
Cabozantinib
15%
Phase I Trial
15%
Systemic Chemotherapy
15%
Active Agent
15%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Cisplatin
70%
Paclitaxel
69%
Diseases
63%
Phase II Trials
52%
Vinblastine
46%
Ifosfamide
45%
Transitional Cell Carcinoma
44%
Prostate Cancer
43%
Castration Resistant Prostate Cancer
40%
Carcinoma
38%
Malignant Neoplasm
37%
Bladder Cancer
32%
Germ Cell Tumor
31%
Overall Survival
28%
Germ Cell Cancer
28%
Prostate Specific Antigen
25%
Neoplasm
25%
Etoposide
24%
Doxorubicin
22%
Progression Free Survival
21%
Docetaxel
21%
Everolimus
20%
Clinical Trial
20%
Renal Cell Carcinoma
19%
Androgen
17%
Carboplatin
17%
Gemcitabine
17%
Methotrexate
16%
Pharmacokinetics
16%
Cabozantinib
15%
Phase I Trials
15%
Gallium Nitrate
14%
Solid Malignant Neoplasm
14%
Estramustine
12%
Maximum Tolerated Dose
11%
Vasculotropin Receptor
11%
Recurrent Disease
11%
Heart Infarction
11%
High Dose Chemotherapy
11%
Metastatic Breast Cancer
11%
Infarction
10%
Interferon
10%
Testis Cancer
10%
Protein Tyrosine Kinase
10%
Small Cell Lung Cancer
10%
Testis Tumor
10%
Estramustine Phosphate
10%
Febrile Neutropenia
9%
Patient History of Chemotherapy
9%
Medicine and Dentistry
Oncology
65%
Cisplatin
58%
Transitional Cell Carcinoma
54%
Diseases
54%
Urothelium
43%
Paclitaxel
39%
Germinoma
36%
Vinblastine
34%
Carcinoma
33%
Prostate Cancer
30%
Phase II Trials
29%
Urothelial Cancer
29%
Bladder Cancer
28%
Overall Survival
27%
Ifosfamide
26%
Clinical Stage
25%
Neoplasm
24%
Combination Chemotherapy
24%
Retroperitoneal Lymph Node Dissection
23%
Gemcitabine
22%
Germ Cell Cancer
21%
Doxorubicin
21%
Castration Resistant Prostate Cancer
20%
Prostate Specific Antigen
18%
Testis Cancer
17%
Malignant Neoplasm
16%
Salvage Therapy
16%
Etoposide
16%
Methotrexate
15%
Health Care Cost
15%
Testis Tumor
15%
Bladder
14%
Clear Cell Renal Cell Carcinoma
12%
Progression Free Survival
12%
Granulocytopenia
12%
Radiation Therapy
12%
High Dose Chemotherapy
12%
Docetaxel
12%
Clinical Trial
11%
Metastatic Breast Cancer
11%
Systematic Review
11%
Chemotherapy
10%
Chemoradiotherapy
10%
Pemetrexed
10%
Everolimus
10%
Clinical Oncology
10%
Patient History of Chemotherapy
9%
Megakaryocyte
9%
Recurrent Disease
8%
Bladder Tumor
8%